Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study-Reference-Cited by-同舟云学术

Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study

Published:2021-09 Issue:9 Volume:22 Page:1290-1300
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Javle Milind,Borad Mitesh J,Azad Nilofer S,Kurzrock Razelle,Abou-Alfa Ghassan K,George Ben,Hainsworth John,Meric-Bernstam Funda,Swanton Charles,Sweeney Christopher J,Friedman Claire F,Bose Ron,Spigel David R,Wang Yong,Levy Jonathan,Schulze Katja,Cuchelkar Vaikunth,Patel Arisha,Burris Howard

Funder

Genentech Inc

Publisher

Elsevier BV

Subject

Oncology

Reference30 articles.

1. New horizons for precision medicine in biliary tract cancers;Valle;Cancer Discov,2017

2. Second-line chemotherapy in advanced biliary cancer: a systematic review;Lamarca;Ann Oncol,2014

3. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial;Lamarca;Lancet Oncol,2021

4. Sequencing of 279 cancer genes in ampullary carcinoma reveals trends relating to histologic subtypes and frequent amplification and overexpression of ERBB2 (HER2);Hechtman;Mod Pathol,2015

5. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer;Swain;N Engl J Med,2015

Cited by 233 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic and Predictive Roles of HER2 Status in Non-Breast and Non-Gastroesophageal Carcinomas;Cancers;2024-09-13

2. Exceptional Response to Pembrolizumab in HER2-Positive Gallbladder Carcinoma with High Tumor Mutational Burden;Journal of Gastrointestinal Cancer;2024-09-10

3. Nanoliposomal Irinotecan With Fluorouracil and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Cholangiocarcinoma: A Phase II Study of the AIO Hepatobiliary-YMO Cancer Groups (NIFE-AIO-YMO HEP-0315);Journal of Clinical Oncology;2024-09-10

4. Exceptional response to pembrolizumab in HER2-positive gallbladder carcinoma with high tumor mutational burden;2024-09-09

5. Chinese national clinical practice guideline on diagnosis and treatment of biliary tract cancers;Chinese Medical Journal;2024-09-04